ecancermedicalscience Editor's Choice for January 2014

MET variant as a prognostic marker in clear cell renal cell carcinoma

The role of molecular biology in the Identification of predictive factors for prostate cancer incidence

Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC)

Predictors of response to mCRPC therapy: where do we stand?

Translational studies of CDK and PARP inhibitors

HER2 positive breast cancer treatment, past and future

Careers in translational research

Role of Bcl-2 family in lymphoid malignancies

Immunotherapy in metastatic kidney cancer

Patient information needs in biomarkers and biobanking

Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction